Literature DB >> 26595284

Checkpoint inhibitors in bladder and renal cancers: results and perspectives.

Fouad Aoun1, Hampig R Kourie2, Spyridon Sideris2, Thierry Roumeguère3, Roland van Velthoven1, Thierry Gil2.   

Abstract

The field of immunotherapy in urinary malignancy is expanding in several directions and checkpoint inhibitors are leading the way. The aim of this report is to highlight the efficacy and safety profile of the two classes of molecules, anti-cytotoxic T-lymphocyte antigen-4 and anti-programmed death receptor-1/programmed death ligand type 1, that are under investigation and represent potential candidates to be used in the near future for the management of bladder and renal cell cancer. The preliminary results as well as the future perspectives of this novel immunotherapy are analyzed. Novel immune checkpoint targets are reviewed as well.

Entities:  

Keywords:  CTLA4; PD1/PDL1; bladder cancer; checkpoint inhibitors; immunotherapy; renal cell carcinoma

Mesh：

Substances：

Year:  2015        PMID： 26595284     DOI： 10.2217/imt.15.91

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


  8 in total

Review 1.  Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.

Authors:  B Bonavida; S Chouaib
Journal:  Ann Oncol       Date:  2017-03-01       Impact factor: 32.976

2.  Brazilian Society of Cardiology Guideline on Myocarditis - 2022.

Authors:  Marcelo Westerlund Montera; Fabiana G Marcondes-Braga; Marcus Vinícius Simões; Lídia Ana Zytynski Moura; Fabio Fernandes; Sandrigo Mangine; Amarino Carvalho de Oliveira Júnior; Aurea Lucia Alves de Azevedo Grippa de Souza; Bárbara Maria Ianni; Carlos Eduardo Rochitte; Claudio Tinoco Mesquita; Clerio F de Azevedo Filho; Dhayn Cassi de Almeida Freitas; Dirceu Thiago Pessoa de Melo; Edimar Alcides Bocchi; Estela Suzana Kleiman Horowitz; Evandro Tinoco Mesquita; Guilherme H Oliveira; Humberto Villacorta; João Manoel Rossi Neto; João Marcos Bemfica Barbosa; José Albuquerque de Figueiredo Neto; Louise Freire Luiz; Ludhmila Abrahão Hajjar; Luis Beck-da-Silva; Luiz Antonio de Almeida Campos; Luiz Cláudio Danzmann; Marcelo Imbroise Bittencourt; Marcelo Iorio Garcia; Monica Samuel Avila; Nadine Oliveira Clausell; Nilson Araujo de Oliveira; Odilson Marcos Silvestre; Olga Ferreira de Souza; Ricardo Mourilhe-Rocha; Roberto Kalil Filho; Sadeer G Al-Kindi; Salvador Rassi; Silvia Marinho Martins Alves; Silvia Moreira Ayub Ferreira; Stéphanie Itala Rizk; Tiago Azevedo Costa Mattos; Vitor Barzilai; Wolney de Andrade Martins; Heinz-Peter Schultheiss
Journal:  Arq Bras Cardiol       Date:  2022-07       Impact factor: 2.667

Review 3.  The current status of checkpoint inhibitors in metastatic bladder cancer.

Authors:  Omar Fahmy; Mohd Ghani Khairul-Asri; Arnulf Stenzl; Georgios Gakis
Journal:  Clin Exp Metastasis       Date:  2016-07-05       Impact factor: 5.150

4.  A pilot study of toceranib/vinblastine therapy for canine transitional cell carcinoma.

Authors:  Sarah B Rippy; Heather L Gardner; Sandra M Nguyen; Emma E Warry; Roberta A Portela; William Tod Drost; Eric T Hostnik; Eric M Green; Dennis J Chew; Juan Peng; Cheryl A London
Journal:  BMC Vet Res       Date:  2016-11-17       Impact factor: 2.741

5.  B7-H3 Promotes the Migration and Invasion of Human Bladder Cancer Cells via the PI3K/Akt/STAT3 Signaling Pathway.

Authors:  Yuchao Li; Guoning Guo; Jie Song; Zhiping Cai; Jin Yang; Zhiwen Chen; Yun Wang; Yaqin Huang; Qiangguo Gao
Journal:  J Cancer       Date:  2017-02-25       Impact factor: 4.207

6.  Development of an Autophagy Score Signature for Predicting Overall Survival in Papillary Renal Cell Carcinoma.

Authors:  Xiang Gu; Xiaojun Chen; Lei Zhu; Wenbo Song; Ali Wang; Junfeng Chu; Tao Wang; Peng Jiang; Yizhi Ge
Journal:  Dis Markers       Date:  2020-11-09       Impact factor: 3.434

7.  Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis.

Authors:  Christopher Ma; Rish K Pai; David F Schaeffer; Jonathan Krell; Leonardo Guizzetti; Stefanie C McFarlane; John K MacDonald; Won-Tak Choi; Roger M Feakins; Richard Kirsch; Gregory Y Lauwers; Reetesh K Pai; Christophe Rosty; Amitabh Srivastava; Joanna C Walsh; Brian G Feagan; Vipul Jairath
Journal:  J Immunother Cancer       Date:  2022-03       Impact factor: 12.469

8.  Activated innate lymphoid cell populations accumulate in human tumour tissues.

Authors:  Maryam Salimi; Ruozheng Wang; Xuan Yao; Xi Li; Xiyan Wang; Yuhui Hu; Xumei Chang; Peiwen Fan; Tao Dong; Graham Ogg
Journal:  BMC Cancer       Date:  2018-03-27       Impact factor: 4.430
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.